1. Medtech Insight
  2. >>Device Area
  3. >>Neurology

I Think, Therefore I Write: Breakthrough Device Turns Thoughts Into Words

 
• By Brian Bossetta

Blackrock Neurotech’s MoveAgain technology platform allows patients who have been silenced by ALS, paralysis and other spinal cord injuries the ability to better communicate via text. The device has been granted breakthrough status by the US FDA.

AI chipset with human brain on computer circuit board.
• Source: Alamy

Most people take the ability to communicate for granted, but for the nearly 5 million people who can’t because of spinal cord injury or disease, it’s a gift that has been taken away. A new technology from Blackrock Neurotech, however, aims to help these patients by giving them a faster way to communicate by turning their thoughts into words.

The company’s MoveAgain Brain Computer Interface (BCI) System, which provides immobile patients the ability to control mobile devices, cursors, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

Medtech Sees Bigger Deals As Early Funding Tightens; LSI Is ‘Cautiously Optimistic’ For 2026

 
• By Marion Webb

Medtech funding in 2025 sees a trend of fewer, yet larger deals with total funding of $3.6bn in Q1, $2.6bn in Q2 and $2.9bn in Q3, said LSI’s Nick Talamantes. In 2026, he expects a continued investor focus on more mature firms in areas of oncology, cardiology and neurology.

BrainsWay Advances With Expanded Depression Indication, New Alcohol Dependence Trial

 
• By Marion Webb

BrainsWay advanced its Deep TMS platform with an FDA labeling expansion for adolescent MDD and the launch of a 200-patient alcohol use disorder trial. The company posted strong Q3 growth and is pursuing new indications and at-home neuromodulation through its Neuralief investment.

Digital Health Roundup: BCIs Surge Ahead, Oura Eyes BP Clearance, AI Faces New Scrutiny

 
• By Marion Webb, Brian Bossetta, Elizabeth Orr, and Shubham Singh

Brain-computer interfaces advance toward trials and commercialization, Oura pushes for FDA-cleared blood pressure monitoring, and regulators weigh AI’s expanding role in mental health and diagnostics amid rising safety concerns.

Subsense Launches Animal Studies To Test Nonsurgical Nanoparticle Brain-Computer Interface

 
• By Marion Webb

Neurotech start-up Subsense started proof-of-concept studies in mice hoping to show by late 2026 that its nonsurgical, nanoparticle-driven brain-computer interface can read and stimulate neural activity and treat conditions such as Parkinson’s and epilepsy.

More from Device Area

LDTs Aimed At Catching Cancers Early Hold Promise In Reducing Late-Stage Diagnoses, Study Shows

 
• By Brian Bossetta

A recent study demonstrates that certain types of blood-based tests that screen for multiple cancers at once have the potential to flip the script on cancer diagnoses, including some of the deadliest types.

Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges

 
• By Barnaby Pickering

Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.

Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market

 
• By Marion Webb

Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.